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DOI 10.1186/s10194-017-0740-3RESEARCH ARTICLE Open AccessA multicenter, open-label, long-term safety
and tolerability study of DFN-02, an
intranasal spray of sumatriptan 10 mg plus
permeation enhancer DDM, for the acute
treatment of episodic migraine
Sagar Munjal1*, Elimor Brand-Schieber1, Kent Allenby1, Egilius L.H. Spierings2, Roger K. Cady3
and Alan M. Rapoport4Abstract
Background: DFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-
enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM). This composition of DFN-02
allows sumatriptan to be rapidly absorbed into the systemic circulation and exhibit pharmacokinetics comparable
to subcutaneously administered sumatriptan. Rapid rate of absorption is suggested to be important for optimal
efficacy. The objective of this study was to evaluate the safety and tolerability of DFN-02 (10 mg) in the acute
treatment of episodic migraine with and without aura over a 6-month period based on the incidence of treatment-
emergent adverse events and the evaluation of results of clinical laboratory tests, vital signs, physical examination, and
electrocardiograms.
Methods: This was a multi-center, open-label, repeat-dose safety study in adults with episodic migraine with and
without aura. Subjects diagnosed with migraine with or without aura according to the criteria set forth in the
International Classification of Headache Disorders, 2nd edition, who experienced 2 to 6 attacks per month with
fewer than 15 headache days per month and at least 48 headache-free hours between attacks, used DFN-02 to
treat their migraine attacks acutely over the course of 6 months.
Results: A total of 173 subjects was enrolled, 167 (96.5%) subjects used at least 1 dose of study medication
and were evaluable for safety, and 134 (77.5%) subjects completed the 6-month study. A total of 2211 migraine
attacks was reported, and 3292 doses of DFN-02 were administered; mean per subject monthly use of DFN-02
was 3.6 doses. Adverse events were those expected for triptans, as well as for nasally administered compounds.
No new safety signals emerged. Dysgeusia and application site pain were the most commonly reported treatment-
emergent adverse events over 6 months (21% and 30.5%, respectively). Most of the treatment-emergent adverse events
were mild. There were 5 serious adverse events, all considered unrelated to the study medication; the early
discontinuation rate was 22.5% over the 6-month treatment period.
Conclusion: DFN-02 was shown to be well tolerated when used over 6 months to treat episodic migraine acutely.
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In the acute treatment of episodic migraine (ie, patients
with fewer than 15 headache days per month [1]), 5-
HT1B1D agonists (triptans) are recommended as first-line
therapy for moderate and severe attacks and for mild at-
tacks that have been unresponsive to analgesics or nonste-
roidal anti-inflammatory drugs in the past [2]. Oral
sumatriptan, the most widely used drug in the triptan class
[3–5], is effective and safe [6], but it may not be an optimal
choice for many attacks. Its poor bioavailability (15%) and
slow absorption (Tmax ≥ 2 h) lead to a slow onset of action
(45–60 min) [7], an issue exacerbated in many patients by
migraine-associated gastric stasis [8–10]. To varying
degrees, poor absorption and relatively delayed onset of
action limit the clinical utility of all oral triptans [4, 6].
For attacks associated with nausea or vomiting, as well
as in patients who cannot tolerate or experience dyspha-
gia with oral triptans, evidence-based guidelines recom-
mend the use of non-oral migraine-specific formulations
[2]. Currently available alternatives, however, are of lim-
ited clinical utility in many patients. Subcutaneous (SC)
sumatriptan 6 mg has good efficacy (60% pain-free at
2 h) and a fast onset of action (10 min post-dose) [11],
but most SC sumatriptan-treated patients (59%) have
injection site reactions, nearly half (42%) experience
atypical sensations (eg, tingling, warm/hot, tightness/
pressure [12]), and many migraineurs are averse to using
injectable formulations [13, 14]. Transdermal sumatrip-
tan, which has been linked with burns and scars at the
application site [15] and has very limited efficacy (18%
pain-free at 2 h [16]), has been voluntarily taken off the
market. With the commercial formulation of sumatrip-
tan intranasal spray (Imitrex® Nasal Spray, Imigran®
Nasal Spray, GlaxoSmithKline), because the drug is not
well absorbed through the nasal mucosa [17] (Tmax
0.88–1.75 h) [18]), its onset of action (30 – 45 min) is
only slightly faster than oral sumatriptan [7]. Poor ab-
sorption is also a problem with intranasal zolmitriptan
(Tmax ~3 h) [19], and sumatriptan nasal powder has
reported a Tmax of 20 min to as long as 2 h [20, 21].
These important clinical limitations, particularly in light
of the attributes of acute treatment that are most im-
portant to migraineurs (rapid onset of action, complete
relief, no recurrence, lack of side effects [22–24]) high-
light a gap in migraine pharmacotherapy and emphasize
the unmet need for a safe and highly effective non-oral
migraine medication with a rapid onset of action.
DFN-02 — sumatriptan 10 mg plus 0.20% 1-O-n-Dode-
cyl-β-D-Maltopyranoside (DDM), a permeation-enhancing
excipient — is a new intranasal migraine treatment under
clinical development that is designed to overcome many of
the limitations to currently available acute medications.
Sumatriptan is a well-known headache medicine that has
been extensively studied and described [4, 5, 25]. DDM, onthe other hand, belongs to a class of surfactants known as
alkylglycosides, which are non-ionic and metabolized to
simple carbohydrates and alcohols or acids that have
shown promise as permeation enhancers for intranasal
medication [26–28]. DDM appears to loosen cell-cell junc-
tions and enhance paracellular movement through the
nasal epithelium by altering mucosal viscosity and mem-
brane fluidity, increasing blood flow, and inhibiting ciliary
beat frequency and drug metabolizing enzymes [28–32].
In a pharmacokinetic (PK) study in healthy subjects,
DFN-02 had a markedly more rapid sumatriptan absorp-
tion profile than commercial intranasal sumatriptan,
systemic exposure was similar to 4 mg SC sumatriptan,
and plasma sumatriptan concentration peaked 5 min
earlier than 4 mg SC and 6 mg SC [33] — results that
suggest it may have efficacy comparable to a 4-mg SC
dose of sumatriptan, which has not yet been demon-
strated in migraine patients. With efficacy expected
based on PK equivalency data, the sole objective of this
study was to evaluate the safety and tolerability of DFN-
02’s unique formulation in the acute treatment of
migraine over a 6-month period, based on treatment-
emergent adverse events (TEAEs), clinical laboratory
results, and electrocardiograms.
Methods
This was a multi-center, open-label, repeat-dose safety
study in adults with episodic migraine with and without
aura. The protocol, the patient information and consent
form, and other relevant study documentation were
approved by the Institutional Review Board (IRB) for
each study center before initiation of the study. Protocol
amendments were approved by the IRB before imple-
mentation or submitted to the IRB for information, as
required. The study followed the Guidelines of the
World Medical Association Declaration of Helsinki in its
revised edition (Brazil, 2013), The International Council
for Harmonisation guidelines for current Good Clinical
Practice, the United States Food and Drug Administration
Code of Federal Regulations, and the demands of national
drug and data protection laws and other applicable regula-
tory requirements. Investigators and study staff recruited
patients at the individual study sites; written consent to
participate was provided after having been informed
about the nature and purpose of the study, participa-
tion/termination conditions, and risks and benefits of
treatment. The study was registered with Clinical-
Trials.gov (NCT02279082).
Subjects
To be enrolled in the study, subjects had to be adults
aged 18 – 65 years diagnosed with acute migraine
according to the criteria set forth in the International Clas-
sification of Headache Disorders, 2nd edition (ICHD-2)
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with or without visual aura per month, with 14 or
fewer headache days monthly and at least 48 h of
headache-free time between attacks; when aura was
present, it could not have lasted longer than 60 min.
Females of childbearing potential had to have a nega-
tive urine pregnancy test, not be lactating, and agree
to practice a reliable form of contraception or abstin-
ence during the study. Males (with female partners)
agreed to practice a reliable form of contraception or
abstinence during the study. Subjects also had to be
willing and able to return to the study site within
72 h of the first use of study medication; record each
attack and each instance of the use of DFN-02 and
rescue medication in a patient paper diary for the
duration of the study; provide written informed
consent; and use the DFN-02 intranasal spray device
correctly after instruction.
Subjects were excluded if they had medication overuse
headache (as defined by ICHD-2); used any botulinum
toxin treatment within 180 days of screening; changed
dosages of migraine preventive medications during
the 30 days before and through screening; took mini-
prophylaxis for menstrual migraine; had hemiplegic
migraine or migraine with brain stem aura or other
forms of neurologically complicated migraine; had a
history of stroke, transient ischemic attack, migra-
lepsy, seizure disorder, ischemic coronary artery disease,
Wolff-Parkinson-White syndrome or arrhythmias associ-
ated with other cardiac accessory conduction pathway
disorders, uncontrolled hypertension, peripheral vascular
disease, ischemic bowel disease, neurological or psychi-
atric impairment, or cognitive dysfunction. They were also
ineligible if they could not differentiate between a
migraine attack and a tension-type or cluster headache;
were intolerant to any formulation of sumatriptan or had
experienced a significant adverse event related to any trip-
tan; had a history of nonresponse to 2 or more triptans.
Subjects were also disqualified for any of the following:
taking medications or having an illness likely to affect the
physiology of the nasal mucosa; abnormal nasal physi-
ology or pathology; intolerance to nasal sprays; severe
renal impairment; serum total bilirubin > 2.0 mg/dL;
serum aspartate aminotransferase, alanine aminotransfer-
ase, or alkaline phosphatase > 2.5 times the upper limit of
normal; 1-year history of alcohol or substance abuse; posi-
tive urine drug screen for illicit drugs or unexplained pre-
scription drugs; received treatment with an investigational
drug or device within 4 weeks of the screening visit or
participated in a central nervous system clinical trial in
the 3 months before screening; tested positive for human
immunodeficiency virus, hepatitis B surface antigen, or
hepatitis C virus; any medical condition that would have
confounded the objectives of the study.Treatment
DFN-02 was provided in a single-use intranasal spray
device designed to deliver 100 μL/spray containing
10 mg of sumatriptan plus 0.20% DDM.
Study conduct
The study involved 9 visits: screening (Day -21 to
Day -1), enrollment (Day 0), initial follow up (within
72 h of treatment), and 6 monthly visits (every 30 ±
3 days). At the screening visit, subjects signed informed
consent and underwent the following assessments:
inclusion/exclusion criteria, demographics, medical his-
tory, physical examination, vital signs, serology, urine
pregnancy test, clinical labs, urinalysis, urine drug test,
12-lead electrocardiogram (ECG), adverse event and
concomitant medications review, and device training
and medication instruction. Hematology, clinical chemis-
try, urinalysis, urine drug screen, and human immunodefi-
ciency virus, Hepatitis B surface antigen, and Hepatitis C
virus antibody analyses were performed at a central
laboratory (ACM Global Central Laboratory, US, 160
Elmgrove Park, Rochester, NY 14624). At each visit, 3
ECG readings were collected, no less than 5 min apart,
and reviewed initially by the investigator for any immedi-
ate concerns, and then by a central reader (ERT, 1818
Market St., Suite 1000, Philadelphia, PA 19103).
Subjects were observed for 21 days after the screening
visit to evaluate whether they satisfied inclusion criteria
and had no medication overuse headache. The screening
period was shortened up to Day -1 if subjects met
inclusion criteria before this time. Subjects continued to
take their normal migraine medication during the screen-
ing period.
At enrollment, screening assessments (with the excep-
tion of demographics) were re-performed; DFN-02 devices
(individually blister packed and labeled), an Instructions
for Use document, and a paper diary were dispensed; and
rescue medication was determined. The quantity of DFN-
02 devices initially dispensed (6 or 12) was determined by
the frequency of attacks (≤3/month = 6 devices; ≥4/
month = 12 devices); at subsequent resupply visits, un-
used devices were counted and additional devices were
dispensed as needed. Throughout the study, additional
instructions on the dispensation of the study medica-
tion were available through an interactive web-response
system.
For the next 6 months, DFN-02 was self-administered
once into 1 nostril (either right or left per subject’s
choice) at the onset of acute migraine pain; for attacks
with aura, subjects were instructed to use DFN-02 at the
onset of pain, not at the onset of aura. If pain relief at
1 h post-dose was insufficient, subjects were permitted
to take either another dose of DFN-02 or rescue medica-
tion. If a second dose of DFN-02 was taken and relief
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permitted; the rescue medication was chosen with the
investigator at screening and adjusted as necessary. No
more than 2 doses of DFN-02 were permitted in a 24-h
period.
During the treatment period, subjects recorded the
migraine pain start and stop for each attack (date and
time), use of DFN-02 (date and time), and use of rescue
medication (date, time, name, and dose) in the paper
diary dispensed to them at each study visit. The paper
diary was reviewed by investigators, and its data were
entered into the electronic case report form by study site
personnel.
Assessments
There were no efficacy variables in this study. Safety var-
iables included the incidence of AEs, clinical laboratory
data (hematology, chemistry, and urinalysis), vital sign
measurements (sitting blood pressure, pulse, respiration
rate, and body temperature), physical examination find-
ings, 12-lead ECG readings, urine pregnancy test results,
study medication use, and concomitant medication use.
The primary endpoint was the incidence of TEAEs
during the 6-month treatment period based on the inci-
dence of TEAEs, clinical laboratory results, and ECG
findings. The number of study medication doses taken
within a migraine attack was determined based on dos-
ing and migraine start/end dates and times recorded by
the subjects; values were corroborated by the site staff.
These data were also reconciled with data in the Drug
Accountability Log, which recorded all used and unused
study medication.
Adverse events were coded by using the Medical
Dictionary for Regulatory Activities (MedDRA, version
17.0) and classified by severity (mild, moderate, severe)
and causality (not related, possibly related, probably
related, definitely related). Treatment-emergent AEs
were defined as AEs with a start date on or after the ini-
tial dose and up to 5 days after the last dose of DFN-02
or events that became worse in severity on or after the
date of the first DFN-02 dose. Severe AEs were defined
as AEs that prevented normal everyday activities and
usually needed treatment or other intervention. Investi-
gators also characterized the seriousness of AEs, and
serious AEs (SAE) were defined as any untoward med-
ical occurrences or effects that, at any dose, resulted in
death or were life-threatening; required or prolonged in-
patient hospitalization, resulted in persistent or signifi-
cant disability/incapacity, or were congenital anomaly/
birth defects. Severe AEs were not necessarily SAEs.
Statistics
All analyses and summaries were produced using SAS
version 9.3 or above (SAS Institute, Cary, NC). Thestudy populations for analysis included all subjects who
were screened (for disposition) and all subjects who
received at least 1 dose of study medication (for all
safety endpoints). Continuous variables were summa-
rized using the number of observations (n), mean, stand-
ard deviation (SD), median, minimum, and maximum.
Categorical variables were summarized using frequency
and percentages of subjects. If there were multiple valid
results at a given visit, the first value at each visit
window was used, unless a test was repeated and the
result suggested that the initial value was an error, in
which case the last observation within the visit window
was used.
Unless otherwise specified, baseline assessment was
the latest available valid measurement taken prior to the
initial dose administration of study medication, generally
Day 0. Missing safety data were not imputed in this
study.
No formal sample size calculation was performed. It
was estimated that at least 150 subjects would need to
be enrolled to ensure that at least 100 subjects com-
pleted the 6-month study period.
Results
Twenty-five US investigator sites participated in the
study. The first subject was enrolled into the study on
06 October 2014, and the last subject completed the
study on 19 August 2015.
Subjects
A total of 229 subjects was screened, 173 subjects met
inclusion criteria, 167 subjects received at least 1 dose
of study drug and were evaluable for safety (96.5%), 134
subjects (77.5%) completed the 6-month treatment
period, and 39 subjects (22.5%) discontinued early from
the study (Fig. 1). The majority of subjects were female
and white (n = 136, 81.4% for both variables). The
median age was 45.0 (19–64) years, and the mean body
mass index was 28.7 (7.0) kg (Table 1). During the 6-
month treatment period, 167 subjects had 2211 attacks,
averaging 13.2 attacks per subject and 2.4 attacks per
month. Those who completed the study (n = 134) expe-
rienced 2036 attacks, averaging 15.2 attacks per subject
and 2.5 attacks monthly.
Medication usage
The median duration of DFN-02 exposure was 181 days.
Over the course of the study, subjects treated 2190
attacks with 3292 doses of DFN-02, averaging 1.5 doses
of DFN-02 per attack. An average of approximately one
third (32%) of attacks per subject was treated with more
than 1 dose of DFN-02. Each month, subjects took a
mean of 3.6 DFN-02 doses, for a 6-month total of 19.7
doses; among those completing the study, the mean
Fig. 1 Disposition of subjects
Table 2 Extent of DFN-02 exposure overall and in subjects who
completed the study
Safety population (N = 167) Completers (n = 134)
Daysa
Mean (SD) 163.3 (48.9)
Median 181
Range 3–241
Monthsb
Mean (SD) 5.4 (1.6)
Median 6.0
Range 0.1–8.0
Doses taken 3292 3031
Doses per patient
Mean (SD) 19.7 (13.0) 22.6 (12.1)
Median 18.0 20.5
Range (1–61) (2–61)
Doses per patient (monthly)c
Mean (SD) 3.6 (2.1) 3.7 (2.0)
Median 3.3 3.4
Range 0.3–10.2 0.3–10.2
SD standard deviation
aDate of study completion or early termination – date of enrollment +1
bNumber of days in the study/30
cNumber of total doses taken/number of months in the study
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per-subject total was 22.6 (Table 2).
Most subjects (58%, 97/167) used rescue medication at
least once in 6 months. The mean total doses per subject
was 2.4 for 6 months, and the mean monthly average
dose per subject was 0.5. The most commonly used
rescue medications were ibuprofen (21%, 35/167); fixed
combinations of aspirin-acetaminophen-caffeine (16.8%,
28/167) and aspirin-butalbital (5.4%, 9/167); and acet-
aminophen (5.4%, 9/167).Table 1 Demographics
Characteristic Total
(N = 167)
n (%)
Sex
Male 31 (18.6)
Female 136 (81.4)
Age (years)a 45.0 (19–64)
BMI (kg)b 28.7 (7.0)
Race
American Indian or Alaska Native 0
Asian 2 (1.2)
Black or African American 25 (15.0)
Native Hawaiian or Other Pacific Islander 1 (0.6)
White 136 (81.4)
Other 3 (1.8)
BMI body mass index
aMedian (range)
bMean (SD)Safety
In total, 71.9% (120/167) of subjects reported 1264
TEAEs in up to 6 months of treatment. About half of
subjects who reported TEAEs (61/120) had mild TEAEs;
only 9 had TEAEs at a level of discomfort that were
determined by the investigator as severe. The severe
TEAEs included dyspepsia, hiatus hernia, application
site pain, gastroenteritis, diverticulitis, sinusitis, post-
traumatic pain (worsening of pain from right shoulder
injury noted in medical history), myalgia (transient
entire body myalgia associated with each occurrence of
study medication dosing), bladder injury (noted during
an open hysterectomy procedure), and menometrorrha-
gia; each severe TEAE affected 1 subject, except for
bladder injury and menometrorrhagia, both of which
occurred in the same subject.
A total of 52.7% of subjects (88/167) experienced study
medication-related events, with TEAEs in 35.9% of
subjects (60/167) considered definitely related, in 11.4%
of subjects (19/167) considered probably related, and in
5.4% of subjects (9/167) considered possibly related. One
migraine TEAE and 3 headache TEAEs were consid-
ered related to study drug. Table 3 lists AEs related to
treatment with DFN-02 that affected at least 2% of
subjects.
Table 3 Treatment-emergent adverse events: total and those occurring in ≥2% of subjects by incidence, severity, and relationship to
study medicationa (N = 167)
Subjects Mild Moderate Severe Not related Possibly related Probably related Definitely related
Overall 120 (71.9) 61 (36.5) 50 (29.9) 9 (5.4) 32 (19.2) 9 (5.4) 19 (11.4) 60 (35.9)
Application site pain 51 (30.5) 38 (22.8) 12 (7.2) 1 (0.6) 0 2 (1.2) 9 (5.4) 40 (24.0)
Dysgeusia 35 (21.0) 30 (18.0) 5 (3.0) 0 0 4 (2.4) 7 (4.2) 24 (14.4)
Application site reaction 9 (5.4) 7 (4.2) 2 (1.2) 0 0 1 (0.6) 2 (1.2) 6 (3.6)
Application site irritation 7 (4.2) 7 (4.2) 0 0 0 1 (0.6) 0 6 (3.6)
Throat irritation 8 (4.8) 6 (3.6) 2 (1.2) 0 0 1 (0.6) 2 (1.2) 5 (3.0)
Chest discomfort 4 (2.4) 4 (2.4) 0 0 1 (0.6) 0 0 3 (1.8)
Nausea 7 (4.2) 2 (1.2) 5 (3.0) 0 1 (0.6) 1 (0.6) 2 (1.2) 3 (1.8)
Dizziness 6 (3.6) 4 (2.4) 2 (1.2) 0 0 3 (1.8) 1 (0.6) 2 (1.2)
Paresthesia 4 (2.4) 3 (1.8) 1 (0.6) 0 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6)
Vomiting 4 (2.4) 2 (1.2) 2 (1.2) 0 2 (1.2) 0 2 (1.2) 0
Diarrhea 4 (2.4) 3 (1.8) 1 (0.6) 0 3 (1.8) 0 1 (0.6) 0
Gastroenteritis viral 6 (3.6) 3 (1.8) 3 (1.8) 0 6 (3.6) 0 0 0
Influenza 4 (2.4) 1 (0.6) 3 (1.8) 0 4 (2.4) 0 0 0
Nasopharyngitis 12 (7.2) 10 (6.0) 2 (1.2) 0 12 (7.2) 0 0 0
Sinusitis 11 (6.6) 4 (2.4) 6 (3.6) 1 (0.6) 10 (6.0) 1 (0.6) 0 0
Upper respiratory tract infection 18 (10.8) 15 (9.0) 3 (1.8) 0 18 (10.8) 0 0 0
Urinary tract infection 5 (3.0) 3 (1.8) 2 (1.2) 0 5 (3.0) 0 0 0
aValues are n (%)
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dysgeusia, application site reaction, upper respiratory
tract infection, nasopharyngitis, and sinusitis (Table 3).
Application site pain (including verbatim of nasal or
nostril burning or stinging) was most common, affecting
30.5% of subjects (51/167) at least once over the 6-
month study period; of those who reported application
site pain, about three quarters (38/51) experienced mild
pain, nearly one quarter (12/51) experienced moderate
pain, and 1 subject experienced severe pain. The next
most common TEAE, dysgeusia, was reported by 21% of
subjects (35/167); the vast majority (30/35) of these sub-
jects had mild dysgeusia, and 5 had moderate dysgeusia.
Severe dysgeusia was not reported.
In the study, there were a total of 94 triptan-related
TEAEs in 32 subjects (19.2%) (Table 3); three quarters of
these subjects (24/32) had mild triptan-related TEAEs,
and one quarter (8/32) had moderate events. Twelve
subjects experienced triptan-related TEAEs that were
considered by the investigator to be definitely related to
study medication. An additional 12 subjects experienced
triptan-related TEAEs that were considered probably
related to study medication, 7 subjects experienced
TEAEs that were considered possibly related to study
medication, and 1 subject experienced a TEAE that was
considered not related to study medication. The most
common triptan-related TEAEs were dizziness and
nausea (3.6%, 6 subjects each).Four subjects experienced 5 SAEs; diverticulitis, chole-
cystitis, and menometrorrhagia each affected 1 subject,
and a fourth had both pyelonephritis and myocardial
infarction. Three SAEs were treatment-emergent (diver-
ticulitis, pyelonephritis, and menometrorrhagia each
affected 1 subject), but all 5 SAEs were considered not
related to study medication.
Five subjects experienced a total of 10 TEAEs leading
to discontinuation from study medication. These TEAEs
included dizziness (1.2%), which affected 2 subjects,
and diarrhea, dyspepsia, nausea, vomiting, feeling jittery,
pain, lethargy, and dyspnea, each of which occurred in
1 subject (0.6%). Another subject was discontinued
due to cholecystitis, an SAE requiring hospitalization,
but it was not treatment-emergent and was considered
not related to the study medication. There were no clin-
ically meaningful trends in mean changes from baseline
or individual changes for any clinical laboratory variable,
vital sign, or ECG.
Discussion
In this 6-month, multicenter, open-label safety study —
during which study medication was used to treat more
than 2000 migraine attacks — DFN-02 was safe and tol-
erable for the acute treatment of patients with episodic
migraine with and without aura. Adverse events with
DFN-02 were similar in pattern, frequency, and severity
to those seen in previous research with triptans and
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safety signals were seen. As expected, dysgeusia and
application site pain were the most commonly reported
tolerability issues; most TEAEs were mild, however,
which may have been a factor in the high rate of study
completion (77.5%).
Although there were no efficacy assessments com-
pleted in this study, findings on other measures indicate
that subjects using DFN-02 appear to have experienced
migraine relief. For example, the vast majority of sub-
jects completed the study, treating multiple attacks over
the 6-month study period, and rescue medication was
only used in about 18% of attacks (2.4 doses for an aver-
age of 13 attacks). Moreover, although repeat dosing of
DFN-02 was permitted at least 1 h after the initial dose,
approximately two thirds of qualifying attacks were
treated with a single dose of DFN-02. Since subjects
were provided with multiple canisters of DFN-02 and
could repeat the dose as needed to control their symp-
toms, the high proportion of attacks treated with a single
dose suggests that DFN-02, which contains only 10 mg
sumatriptan, provided most subjects with adequate
migraine relief.
Previous research with the commercial formulation of
intranasal sumatriptan 20 mg demonstrated good safety
and tolerability; the incidence of individual AEs was
similar to placebo [17, 35]. The persistent exception is
bad, bitter, or unpleasant taste, which affected 19–36%
of subjects in randomized, placebo-controlled studies
[35] and 22%–27% of subjects in a pooled analysis [17].
With DFN-02, dysgeusia was similarly common (21% of
subjects), but symptoms were mostly mild, and no sub-
jects cited it as a reason for discontinuation. Application
site pain with DFN-02 was more common than in previ-
ous research with intranasal formulations (30.5% vs 4%
[17, 35]); these events may be related to the presence of
the permeation enhancer DDM in DFN-02. In clinical
practice, however, the kinetics of DFN-02 have been
shown to be about the same as sumatriptan 4 mg SC
[33], with migraine patients expected to experience simi-
lar times to onset of action and rates of pain freedom,
which suggests that the risk of site reactions with DFN-
02 could be about 30% lower than with comparable
acute treatments, such as 4 mg SC (30.5% vs 43% [36]).
Since most TEAEs were mild, the study completion rate
was high, and few subjects withdrew, the relative fre-
quency of application site pain does not seem a likely
barrier to care with DFN-02.
This study provides clinically useful data but has some
limitations. Subject eligibility was based on ICHD-2,
while the current version is ICHD-3 (beta). At the time
of the study set-up, ICHD-3 (beta) [1] was newly avail-
able and still collecting feedback from experts; therefore,
the study proceeded using the previous version.Nevertheless, ICHD-2 and ICHD-3 (beta) are identical
with respect to diagnosis of acute episodic migraine.
Lacking a placebo control, the true incidence of AEs re-
lated to DFN-02 could not be determined. Additionally,
in the absence of a direct comparison of DFN-02 with the
commercially available intranasal formulation of sumatrip-
tan, it was not possible to assess the relative safety of
DFN-02 and marketed products. Given the well-
established safety profile of intranasal sumatriptan, how-
ever, it is unlikely that any of these factors influenced the
generalizability of these results or the long-term safety
outcomes seen with DFN-02.
Sumatriptan is widely used and has been available in
oral tablet, nasal spray, and injectable formulations for
decades [25]. However, nearly 30% of migraineurs report
dissatisfaction with acute therapies [37], with the most
common complaint being that pain relief takes too long
[22]; close to 90% of patients express a willingness to try
new acute treatments [23, 24]. Because the PK of DFN-
02 are compatible with a possible rapid onset of action
and a favorable safety profile without the disadvantages
associated with oral or SC therapies, DFN-02 may be
useful for patients who prefer not to treat their condi-
tion with injectable medications, as well as patients in
whom nonresponse, dysphagia, nausea, or vomiting pre-
clude the use of orally administered drugs. As seen with
similar triptan delivery systems [38, 39], ease of use may
make DFN-02 especially convenient for treatment at
home, work, and while traveling [35].Conclusions
In this multicenter, open-label safety study, DFN-02, a
novel intranasal spray formulation composed of suma-
triptan 10 mg and a permeation-enhancing excipient
DDM, was safe and tolerable for the acute treatment of
episodic migraine over a 6-month study. Adverse events
with DFN-02 were similar in pattern, frequency, and se-
verity to those seen in previous research with intranasal
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